Bizaxofusp

Summary

Bizaxofusp (also known as IL‑4(38‑37)-PE38KDEL, MDNA55) is an investigational fusion protein that couples a circularly permuted interleukin‑4 ligand to a truncated Pseudomonas exotoxin (PE38KDEL). It is designed to bind interleukin‑4 receptors that are over‑expressed on many solid tumours and certain leukaemias, delivering a potent toxin directly to the cancer cells. Current research focuses on intratumoral delivery for cancers such as breast, head‑and‑neck, glioma and chronic lymphocytic leukaemia.

Mechanism of Action

The IL‑4 component of Bizaxofusp binds with high affinity (Kd 0.2–1 nM) to the type II IL‑4 receptor β‑chain complex on tumour cells. After receptor‑mediated endocytosis, the PE38KDEL toxin fragment ADP‑ribosylates elongation factor‑2, halting protein synthesis and triggering rapid cell death. The KDEL sequence retains the toxin in the endoplasmic reticulum, enhancing cytotoxic potency while sparing cells lacking the receptor.

What the Research Shows

Pre‑clinical studies demonstrated that breast carcinoma, head‑and‑neck squamous cell carcinoma, glioma and chronic lymphocytic leukaemia cells express IL‑4R and are killed by Bizaxofusp at nanomolar concentrations (IC50 0.005–1.5 nM). Intratumoral or intraperitoneal injection caused dose‑dependent tumour regression in xenograft models of breast cancer and SCCHN without visible toxicity. Multidrug‑resistant lines remained sensitive except those over‑expressing MRP1, a resistance that could be reversed with MRP1 inhibitors. A phase‑I glioma trial (nine patients) reported local tumour necrosis, one complete remission lasting >18 months, and no systemic or neuro‑toxic effects, though some patients required surgery for intracranial pressure.

Reported Benefits

Bizaxofusp offers targeted delivery of a potent toxin to IL‑4R‑positive tumours, achieving cytotoxicity at sub‑nanomolar concentrations and showing activity against many multidrug‑resistant phenotypes. Intratumoral administration limits systemic exposure, and early glioma data suggest the potential for durable tumour necrosis and remission without systemic toxicity.

Limitations of the Evidence

Evidence is largely pre‑clinical; clinical experience is limited to a small glioma cohort. Efficacy depends on sufficient IL‑4R expression, which varies among tumour types and is absent in normal breast epithelium. Resistance via MRP1 expression may limit activity in some tumours. Intratumoral delivery restricts use to accessible lesions and requires specialised catheter placement.

Safety Considerations

Animal studies and the glioma phase‑I trial reported no systemic toxicity. Local adverse effects included tumour‑related necrosis, edema and, in several patients, increased intracranial pressure necessitating craniotomy. No neuro‑toxicity to normal brain tissue was observed. Potential resistance mechanisms (e.g., MRP1) could alter safety if higher systemic exposure were required.

How It Is Administered

Bizaxofusp is administered as a recombinant protein directly into the tumour (intratumoral infusion), typically via stereotactically placed catheters over several days. Pre‑clinical work also used intraperitoneal injection, but clinical protocols have focused on local delivery to minimise systemic exposure.

Routes of Administration

Goals & Uses

• Targeting EGFR-overexpressing solid tumorsOncologyLow
• Treatment of recurrent glioblastoma multiforme (GBM)OncologyModerate
• Tumor debulking prior to additional therapyOncology Combination StrategyLow

Contraindications

• Hypersensitivity to Pseudomonas exotoxin componentsImmunologicHigh
• Coagulopathy or bleeding diathesisHematologicModerate
• Active systemic infectionInfectiousHigh
• Poor performance status precluding neurosurgeryClinicalModerate

Adverse Effects

• HeadacheNeurologicCommonPain in the head or upper neck
• SeizuresNeurologicalUncommon
• FatigueGeneralCommonLow energy or tiredness
• Intracranial hemorrhageNeurologicalRare
• Cerebral edemaNeurologicalCommon
• Neurological deficits (focal)NeurologicalCommon

Drug Interactions

• Immunosuppressive agentsLow
• Corticosteroids (e.g., dexamethasone)Low

Population Constraints

• EGFR-negative tumor patientsBiomarker / Tumor BiologyRelative
• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Patients with prior severe neurological compromiseClinicalRelative

Regulatory Status

• European UnionInvestigationalNot approved in the European Union; investigational use only.
• United StatesInvestigationalFDA Breakthrough Therapy Designation granted for recurrent glioblastoma. Not approved; Phase 2/3 clinical trials conducted.
• United KingdomInvestigationalNot approved by MHRA; investigational status only.

Bizaxofusp received FDA Breakthrough Therapy Designation for recurrent glioblastoma. It is not currently approved in any jurisdiction. Phase 2/3 trials have been conducted. Previously developed by Medicenna Therapeutics.

Evidence & Sources

• Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo
  Journal ArticleLowLeland P, et al.2000-01-01T00:00:00.000000Z
• Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models
  Journal ArticleLowStrome SE, et al.2002-01-01T00:00:00.000000Z
• CLL immunotoxins
  Journal ArticleUngradedFrankel AE, Kreitman RJ2005-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleLowBayés M, Rabasseda X, Prous JR2004-01-01T00:00:00.000000Z
• Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1
  Journal ArticleLowde Jong MC, et al.2003-01-01T00:00:00.000000Z
• Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma
  Journal ArticleModerateRand RW, et al.2000-01-01T00:00:00.000000Z

Frequently Asked Questions